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A pilot study of mitomycin, cisplatin and continuous infusion
5-fluorouracil (MCF) in advanced non-small-cell lung cancer
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Su_niary A pilot study of continuous infusional 5-fluorouracil 200 mg m' per 24 h by ambulatory pump
and Hickman line for the entire treatment cycle with mitomycin C 8 mg m- i.v. on day I and cisplatin 75
mg m' i.v. on day 1, both repeated every 28 days, was carried out in 31 previously untreated patients with
advanced non-small-cell lung cancer (NSCLC). Of 31 patients assessable for response, one attained a complete
remission and eight a partial remission, an overall response rate of 29%. Haematological toxicity was minimal,
with only 3% ofpatients developing WHO grade III IV neutropenia and 13% grade III LV thrombocytopenia.
Significant side-effects included moderate to severe emesis (41%), mucositis (34%), diarrhoea (31°%) and
palmar-plantar syndrome (14%). Seven patients (23%) had Hickman line complications requiring line
removal. Continuous infusional chemotherapy with this regimen is active in advanced non-small-cell lung
cancer, but its complexicity and associated treatment toxicity offer little advantage over equally active but
simpler and less toxic cisplatin-based regimens.
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Combination chemotherapy is increasingly being accepted as
having a role in the management of advanced non-small-cell
lung cancer (NSCLC). A number of recent trials have shown
a survival benefit for combination chemotherapy over best
supportive care (Cormier et al., 1982; Rapp et al., 1988;
Cartei et al., 1993) and a recent overview analysis confirmed
a significant, although modest, survival benefit in favour of
chemotherapy (Souquet et al., 1993). No one regimen has
been shown to be superior to others in terms of survival in
the treatment of advanced NSCLC, although cisplatin-based
regimens appear to offer the best response rates (Veronesi et
al., 1988; Luedke et al., 1990). Common regimens in use
include cisplatin/etoposide (Ruckdeschel et al., 1986), MVP
(mitomycin, vinblastine, cisplatin) (Ruckdeschel et al., 1986)
and MIC (mitomycin, ifosfamide, cisplatin) (Cullen et al.,
1988). In our own institution we have developed a moderate-
dose MVP regimen that appears to be effective, cheap and
very well tolerated (Hardy et al., 1989).
Infusional 5-fluorouracil (5-FU) has been shown to be
more effective than bolus injection in colon cancer (Lokich et
al., 1989) and has resulted in very high response rates when
used in conjunction with epirubicin and cisplatin (ECF) in
the treatment of advanced gastric cancer (Findlay et al.,
1994) and carcinoma of the breast (Smith et al., 1993). In
order to try and improve on the above results in advanced
NSCLC, we undertook a pilot phase II study of continuous
infusion 5-FU (in the same dose as had been shown to be
effective in the above studies) in conjunction with cisplatin
and mitomycin C (another agent with known single-agent
activity in NSCLC). The aim of the study was to determine
response rate, feasibility of administration, toxcicity and effect
on survival of this regimen.
Materis and methods
Patient characteristics and eligibility'
Thirty-one sequential patients with advanced NSCLC refer-
red to the Lung Unit at the Royal Marsden Hospital were
entered into this pilot study between May 1991 and
December 1992. Eligibility criteria included histologically or
cytologically proven NSCLC, inoperability, WHO perfor-
mance status 0-3, normal full blood count, satisfactory renal
function (EDTA>60 ml min-') and liver function (liver
function tests less than twice upper limit of normal). Patients
were required to be either stage IIIB or stage IV according to
the criteria of Mountain (1986). Patients with responding
local disease following chemotherapy were considered for
either surgery or local radiotherapy if appropriate.
There were 19 males and 12 females (median age 53).
Median WHO performance status was 1 (range 0-3). Twelve
patients had stage IIIB disease and 19 had stage IV disease.
Classification according to histology was as follows:
adenocarcinoma, 21 patients; large-cell carcinoma, four
patients; squamous cell carcinoma, six patients. Three
patients had received prior treatment. One had relapsed 8
months after lobectomy, and two had received local palliative
radiotherapy. In addition, one patient had been treated with
mantle irradiation for stage IA lymphocyte-predominant
Hodgkin's disease 15 years before his presentation with
NSCLC. Patient characteristics are listed in Table I.
Treatment regimen
All patients received the following regimen: mitomycin C 8
mgm-2 i.v. on day 1, cisplatin 75 mgm- i.v. on day 1
repeated every 28 days, 5-FU given intravenously as a con-
tinuous infusion of 200 mg m-2 via an ambulatory Infumed
pump (Neurotechnics) and indwelling Hickman line into a
subclavian vein. Standard intravenous pre- and post-
treatment hydration was given with cisplatin. Patients
received prophylactic antiemetic therapy with high-dose
metoclopramide and dexamethasone immediately before the
commencement of cisplatin and for 24 h afterwards, followed
by 3 days of oral metaclopramide and dexamethasone.
Patients failing to respond to this regimen were treated with
a 5-HT3 antagonist and dexamethasone. They were instructed
on the use of the pump by specialist nurses and changed their
5-FU infusion bags once weekly at home.
Renal function was checked with [5lCr]EDTA clearance
before alternate courses and the dose of cisplatin reduced as
follows: EDTA 60 mlmin-', full dose; 40-59 mlmin-',
dose of cisplatin in mg = EDTA clearance in mlmin'; <40
ml min-', no treatment.
The median number of chemotherapy cycles received by
the patients was 4 (range 1-7). Treatment was continued to
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six cycles for those patients who achieved an objective res-
ponse and/or symptomatic relief, but discontinued earlier in
the event of progressive disease or unacceptable toxicity.
Patients developing palmar-plantar erythema on con-
tinuous infusion 5-FU were treated initially with pyridoxine
50 mg t.d.s. Ifthis did not settle 5-FU was discontinued for 1
week and restarted with a 50 mg m2 dose reduction. If
patients developed mucositis or diarrhoea, 5-FU was discon-
tinued until symptoms subsided, and restarted with a 50
mg m2 dose reduction.
Assessment ofresponse and toxicity
The study end points were response, toxiaty and survival. All
patients underwent pretreatment physical examination,
mesurement of full blood count, plasma electrolytes, urea
and creatinine, serum liver function tests, [5lCrJEDTA
clarance and chest radiogaphy. Computerised tomography
was carried out when the disease was not easily evaluable on
chest radiographs. Patients had chest radiography, full blood
count and serum biochemistry before each treatment and
were at this time for objective response and toxicity
according to standard WHO criteria (Miler et al., 1981).
Complete response (CR) was defied as the disappearance of
all known disease for at least 4 weeks. Partial response (PR)
was defined as a reduction in the product of two diameters of
the tumour by at eat 50% for at least 4 weeks. Stable
diseas (SD) was defined as a less than 50% decrease or less
than 25% increase in the size of the measurable disease
without the appearance of new lesions.
Response duration and survival were calculated from the
date offirst treatment using the standard life table method of
Kaplan and Meier (1958).
Assessment ofsymptomatic response
Tumour-related symptoms were recorded at the start of treat-
ment under the general headings malaise, pain, cough, dysp-
noea or other, which was the specified. Symptoms were then
reassessed following each course of treatment with patients
asked to grade change in symptoms using simple descriptive
criteria as follows: (i) complete disappearance of symptoms
(CR); (ii) good improvement of symptoms (PR); (iii) minor
or no change in symptoms (NC); (iv) worse (PD).
Ethical considerations
This study was conducted in accordance with the Declaration
of Helsinli and was approved by the Royal Marsden Hos-
pital Ethical Committee. Witnessed, informed consent was




Nine of 31 patients (29%; 95% CI 13-45%) achieved an
objective response with one CR and eight PRs. Six patients
progressed on chemotherapy, two patients dying of progres-
sive disease before completion of the first treatment cycle.
Four of 12 patients (33%) with locally advanced disease
(stage HIB) responded compared with 5 of 17 patients (29%)
with metastatic disease (stage IV). Median duration of res-
ponse was 11 months. Details of response by stage are shown
in Table H. Median survival for all patients was 7 months (6
months for HIB patients, 4 months for stage IV patients).
Four out of 12 patients with stage IHB disease responded.
One of these attained a complete remission but she became
severely depressed and was unable to tolerate any further
local treatment. One patient attained a partial remisson,
down-staging her tumour sufficiently to enable lobectomy to
be carried out. Unfortunately, she developed a cerebral
metastasis shortly after her operation and died 3 months
later. One patient responded but was not felt to be fit enough
to tolerate radical radiotherapy. The other responding patient
received a full course of radical radiotherapy.
Symptomatic response
Twenty-one patients had complete disappearance or good
improvement in at least one tumour-related symptom (70%;
95% CI 54-86%). Eight of 12 patients (67%) with stage
IHB disease had a symptomatic response, compared with
13/18 patients (72%) with stage IV disease. Response for
specific symptoms was as follows: malaise, 7/15 patients
(47%); pain, 11/20 patients (55%); cough, 15/21 patients
(71%); dyspnoea, 13/23 patients (57%). Seven patients (23%)
had progression of symptoms during chemotherapy. Details
of symptomatic response are given in Table IHI.
Eighteen of 21 responding patients (86%) had a symp-
tomatic response after two courses of chemotherapy. Ten of
these had further symptomatic improvement with more treat-
ment. Only three patients who faied to achieve symptomatic
relief with two courses of treatment (14%) gined symp-
tomatic response with further treatment, all achieving max-
imum response after three cycles.
Table H Tumour response by stage
Overall Total
CR PR response SD PD No.
IIIB 1 3 (33%) 7 1 12
IV - 5 (26%) 9 3 19
Overall 1 8 (29%) 16 4 31
Table m Overal symptomatic response
Stage CR PR NC PD Total no.
ITIB 2 6 - 4 12
IV 5 8 2 3 18
Total 7(23%) 14(47%) 2(7%) 7(23%) 30MCF in advanced non-small-cl lug cancer
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Seven of nine patients (78%) with an objective response to
treatment gained symptomatic relief. However, 14 of 21
patients (67%) with no change or progressive disease on
objective response assessment also gained symptomatic relief.
Toxicityi
This regimen had a low incidence of bone marrow toxicity,
with only one patient developing WHO grade I1IiIV neut-
ropenia and four developing WHO grade III/IV throm-
bocytopenia. Two patients developed significant neutropemnc
infection, but there were no toxic neutropenic deaths. The
most significant non-haematological toxicity was emesis, with
12 patients (41%) developing grade III/IV nausea or
vomiting. Although seldom severe, diarrhoea, mucositis, and
palmar-plantar erythema were experienced by 31%, 34%
and 14% of patients respectively. Only two patients
developed significant alopecia, and there were few other
significant side-effects. A detailed outline of the toxicity
profile is given in Table IV.
Dose reductions
Eight patients (26%) required a 25% dose reduction of at
least one drug. In two cases cisplatin dose was reduced due
to a reduction in EDTA clearance below 60 ml min-'. In
three patients 5-FU was reduced because of palmar-plantar
erythema, and in three patients because of grade III throm-
bocytopenia. No patient required cessation of treatment
because of treatment-induced toxicity.
Hickman line complications
Seven patients (23%) experienced significant Hickman line
complications, in six of whom the line required removal. Two
patients developed grade III line infections and three patients
developed subclavian venous thrombosis requiring line
removal, one of whom also developed a pulmonary embolus.
In two patients the catheter slipped from its original position
into the jugular vein and needed to be removed. One of these
patients also developed a pneumothorax post-Hickman line
insertion, requiring insertion of a chest drain.
The use of 5-FU as a single agent in NSCLC has shown little
activity with response rates of less than 10% (Selawry, 1973;
Kris et al., 1985) and there has seemed little rationale for its
use in this disease when given as a bolus injection. There
have been two previous reports of the use of 5-fluorouracil as
a short infusion in combination with cisplatin and etoposide
in advanced NSCLC, neither suggesting an advantage in
terms of either response rate or survival compared with
previous established cisplatin-based regimens (Flaherty et al.,
1991; Lynch et al., 1993). Continuous infusional 5-FU, how-
ever, has not previously been assessed as front-line therapy in
this setting. Giving 5-FU as a continuous infusion allows
increased dose intensity without a significant increase in tox-
icity, and recent results in colon cancer (Lokich et al., 1989),
gastric cancer (Findlay et al., 1994) and breast cancer (Smith
et al., 1993) suggest increased activity with this approach.
This study was designed to see if a similar approach in
combination with other known active agents would lead to a
regimen with improved efficacy in advanced NSCLC.
The response rate obtained with this regimen does suggest
significant activity in this tumour type, however it appears no
Table IV Toxicity - worst grade for all courses
WHO grade
0 1 2 3 4 %1-2 %3-4
Haematological
Anaemia 5 7 18 1 - 81 3
Leucopenia 18 5 7 1 - 39 3
Thrombocytopenia 19 1 7 1 3 26 13
Non-haematological
Emesis 2 7 8 10 2 52 41
Infection 19 4 4 - 2 28 7
Mucositis 19 7 2 1 - 31 3
Diarrhoea 20 7 - - 31 -
Alopecia 15 5 7 2 - 41 7
Neuropathy 28 1 - - - 3 -
Nephropathv 22 6 - I - 21 3
Palmar-plantar 25 2 2 - - 14
more effective than other simpler cisplatin-based regimens
(Ruckdeschel et al., 1986; Cullen et al., 1988; Hardy et al.,
1989). Although haematological toxicity was minimal, there
were a number of troublesome side-effects associated with
MCF. These included a significant proportion of patients
with moderate to severe emesis. and the development of
mucositis. diarrhoea and palmar-plantar syndrome (all
related to the infusional 5-FU). The incidence of serious
Hickman line complications was also greater than we had
anticipated, although we may have been unlucky as a similar
incidence has not been seen in other reported studies using
infusional treatment in other tumour types (Lokich et al.,
1989; Smith et al., 1993; Findlay et al., 1994). Nevertheless,
these toxicities all impinge on patient quality of life while on
chemotherapy. an important consideration in the develop-
ment of a regimen primanrly concerned with palliation and
symptom control.
The overall symptomatic response rate in this study was
70%. This confirms previous studies at our institution sug-
gesting that approximately two-thirds of patients achieve
useful symptomatic benefit with palliative chemotherapy, in-
cluding patients who may not have responded according to
objective response cntenra (Hardy et al.. 1989; Ellis et al..
1995). As in these studies. the vast majority of patients
attained symptomatic relief after two courses of
chemotherapy, with only a small number achieving a res-
ponse after further treatment. This reinforces our impression
that, in general, palliative chemotherapy should be stopped
after two cycles in patients who have not achieved significant
symptomatic relief.
Although active in advanced non-small-cell lung cancer
and offering useful symptomatic relief in a significant propor-
tion of patients, the toxicity profile and complexity of MCF
suggests little benefit over other previously reported
regimens. We therefore feel that there is little to be gained by
taking this regimen forward into large randomised studies.
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